merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for potentially better treatments</answer>
<question_number>3</question_number>
<answer>There is no correlation between amyloid plaque removal and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>It raises concerns about Kisunla's safety</answer>
<question_number>5</question_number>
<answer>The expectation that patients can stop Kisunla after their plaques are cleared</answer>
<question_number>6</question_number>
<answer>It might discourage participation in trials for other treatments</answer>
<question_number>7</question_number>
<answer>Patients can stop the drug after it clears amyloid plaques</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Intermediate tau levels in trial participants</answer>